Hikma continues doubling down on its strategic turn towards more complex products and injectables while also forecasting better days for its generics division, based on its recent presentation at this year’s J.P. Morgan Healthcare Conference.
As of now, the company’s injectables division generates “well over” $1bn in revenue, and makes up almost